CN106491718A - 制取自两种植物药的组合物及其用途 - Google Patents
制取自两种植物药的组合物及其用途 Download PDFInfo
- Publication number
- CN106491718A CN106491718A CN201611173840.3A CN201611173840A CN106491718A CN 106491718 A CN106491718 A CN 106491718A CN 201611173840 A CN201611173840 A CN 201611173840A CN 106491718 A CN106491718 A CN 106491718A
- Authority
- CN
- China
- Prior art keywords
- compositionss
- ethanol
- hour
- present
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 90
- 239000003814 drug Substances 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 20
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 12
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 12
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 238000010992 reflux Methods 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 230000006837 decompression Effects 0.000 claims abstract description 6
- 238000004064 recycling Methods 0.000 claims abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 26
- 235000013305 food Nutrition 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 239000008280 blood Substances 0.000 abstract description 26
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000000203 mixture Substances 0.000 abstract description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 18
- 239000008103 glucose Substances 0.000 abstract description 18
- 238000011161 development Methods 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 2
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 24
- 239000009633 chimonin Substances 0.000 description 20
- 229930189907 rotundine Natural products 0.000 description 16
- 230000009471 action Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000000144 pharmacologic effect Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000012567 medical material Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- -1 Novo Nordisk) Chemical compound 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000008517 radix Trichosanthis Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 2
- 235000019890 Amylum Nutrition 0.000 description 2
- 241000717739 Boswellia sacra Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- 240000008620 Fagopyrum esculentum Species 0.000 description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 244000153234 Hibiscus abelmoschus Species 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001669 calcium Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VQMZQKBLIKANMK-IKFJEIPGSA-N (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16S,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol (2S,3R,4S,5S,6R)-2-[(2R,3S,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1S,2R,4R,5'S,6R,7R,8S,9S,12R,13S,16R,18S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C[C@H]1CC[C@@]2([C@@H]([C@@H]3[C@H](O2)C[C@H]4[C@@]3(CC[C@@H]5[C@@H]4CC[C@@H]6[C@@]5(CC[C@H](C6)O[C@H]7[C@H]([C@H]([C@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C)OC1.C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C)OC1 VQMZQKBLIKANMK-IKFJEIPGSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 235000008375 Decussocarpus nagi Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000009451 Hyperglycemic Hyperosmolar Nonketotic Coma Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001093152 Mangifera Species 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 244000132436 Myrica rubra Species 0.000 description 1
- 235000014631 Myrica rubra Nutrition 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000173853 Sanguisorba officinalis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000029486 Stephania sinica Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008782 xin-kang Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种制取自芒果叶和华千金藤的组合物,按重量份取芒果叶0.3份~7份,华千金藤0.1~5份,加50v/v%~90v/v%乙醇回流提取2次,第1次为8倍量50v/v%~90v/v%乙醇,1~3小时,第2次为6倍量50v/v%~90v/v%乙醇,1~2小时,滤过,合并2次滤液,减压回收乙醇至无醇味,继续减压浓缩至50℃±5℃时相对密度为1.20~1.34,得提取物。经动物实验证明,本发明组合物能改善血糖和糖化血红蛋白,具有药物的开发前景。
Description
技术领域
本发明涉及一种取自植物的组合物,尤其涉及一种芒果叶和华千金藤相配伍的组合物,以及其提取物和活性成分在制取预防和治疗糖尿病组合物中的应用。
背景技术
糖尿病(Diabetes Mellitus,DM)是一种因体内胰岛素绝对或者相对不足所导致的一系列临床综合症。该病在发展进程中还会引起一些并发症,如:低血糖症(Hypoglycemia)、酮症酸中毒(Ketoacidosis)、非酮高渗性昏迷(NonketoticHyperosmolar Coma)、心血管疾病、慢性肾衰竭、视网膜病变、神经病变及微血管病变等。糖尿病治疗常用的药物主要有三大类:生物药类,如:胰岛素(Insulin);化学药,如:磺酰脲类(Sulfonylurea)、双胍类(Biguanide)、格列酮类(Glitazone)和中成药类。限于目前尚没有较为成熟的胰岛素非注射给药技术,其使用仍以注射为主,且注射过程也存在安全性风险。化学类药物虽具有较强的降血糖作用,但对肝、肾等毒副作用大,还容易导致心血管并发症加重。此外,还有一些药物,如:胰高血糖素类多肽(Glucagon-like peptide 1,GLP-1)、脂酰基化胰高血糖素类多肽(NN2211,Novo Nordisk)、Exendin-4(Amylin)和聚乙二醇修饰的Exendin-4(中国发明专利申请00809516.7)等,长期给药后虽能有效控制血糖、降低糖化血红蛋白HbA1c数值和改善β胰岛细胞功能,但由于这些分子还同样作用于中枢神经受体,所以给药后呕吐和眩晕的症状较难避免,且给药方式仍以注射为主。另一类DPPIV酶抑制剂,虽能口服,但其将对生物体内的一大类酶均产生抑制作用,从而会使体内脂肪分布发生变化,且给药的实际效果也相对较差。
中国发明专利申请93100485.3公开了一种荞麦保健食品,以苦荞麦粉为基料,辅以大豆蛋白粉,再添加枸杞、人参、知母、活性钙等中草药天然成分,其配方重量百分组成为:苦荞麦面粉60-80%、大豆蛋白粉15-30%、枸杞多糖0.5-2.5%、知母皂甙0.2-0.5%、人参多糖0.5-1.5%、活性钙1.2-4.3%。组成的食品对糖尿病具有治疗作用。该保健食品以荞麦为主,能对糖尿病患者的饮食起到一定作用,但在治疗方面的效果有待进一步的实验证实。
中国发明专利ZL95116521.6公开了一种双补降糖胶囊及其制作方法,使用熟地、黄芪、枸杞子、丹参、黄柏、知母和肉桂等20味原料药,经特殊炮制和加工而成。该降糖胶囊由中药材粉碎后制成,由于含有的纤维素含量多,而能减缓糖的吸收,加入附子和肉桂二药材后使得药物降糖效果更为显著,是该发明的重点所在。
中国发明专利申请99126988.8公开了一种专冶糖尿病降糖胶囊,以生地、天花粉、玄参、知母、黄柏、黄连、鹿茸、边桂、山药、石膏和干藕粉等药材为主要组分,治疗由糖尿病引起的上消、中消、下消和多食多尿等病症。
中国发明专利申请02107203.5公开了一种治疗2型糖尿病的复方中药制剂,以葛根、天花粉、苍术、玄参、生黄芪、山药、生石膏、肉桂、熟附片、鬼箭羽、地鳖虫、桑寄生、蚕茧、炮山甲、水蛭、血竭、菝葜、知母、绞股蓝、生地、麦冬、赤芍、地骨皮、制大黄等天然中药材为原料,通过粉碎、煎煮、烘干、灭菌等工序制成,用于II型糖尿病及其并发症的治疗。
中国发明专利申请200310110332.7公开了一种治疗糖尿病的药物参芪山药膏及其制备方法,由“君”药:山药和人参;“臣”药:海龙、海马、阿魏、乳香、没药、红花、肉桂、珍珠、人工麝香、天花粉、黄柏、黄芪、芒果叶和番石榴叶;以及“使”药:冰片等药材共同配伍而成。将山药、人参、天花粉、黄柏、黄芪、芒果叶和番石榴叶等药材的碎段混匀,浸泡于麻油中,三天后经加热,过滤,在滤油中加入红丹,再搅匀,收膏;将药膏加入冷水中,不断搅拌,挤压换水;取药膏用文火熔化,加入珍珠层粉、冰片粉、人工麝香、海龙、海马、阿魏、乳香、没药、红花和肉桂等药材的细粉,搅匀,分摊在无纺布上制成膏药。所制得的药膏益气养阴、生津止渴,具有治疗II型糖尿病的功效。
芒果叶为漆树科植物杧果Mangifera indica L.的干燥树叶。主要功能主治为消积滞,疏风止咳,传统常用于治疗消化不良、咳嗽和皮肤痒等。人们尚未认识到其对预防何治疗糖尿病的药理作用。
华千金藤为防己科植物华千金藤Stephania sinica Diels的干燥块根。具有清热解毒,散瘀止痛功效,用于上呼吸道感染,咽喉炎,胃痛,急性肠胃炎,细菌性痢疾,疟疾,风湿疼痛,外伤疼痛等;外用治跌打损伤,毒蛇咬伤,疮疡肿毒等。人们也尚未认识到其对预防何治疗糖尿病的药理作用。
发明内容
本发明的一个目的在于提供一种组合物,将芒果叶和华千金藤相配伍,具有改善血糖和糖化血红蛋白的药理作用。
本发明的另一个目的在于提供一种组合物,芒果叶和华千金藤的提取物具有改善血糖和糖化血红蛋白的药理作用。
本发明的再一个目的在于提供一种组合物,其以芒果苷和罗通定为活性成分,具有改善血糖和糖化血红蛋白的药理作用。
本发明的又一个目的在于提供一种组合物,将芒果叶和华千金藤相配伍,及其提取物等活性成分而制成药物、食品和保健品,用于糖尿病的预防和治疗。
本发明的又一个目的在于提供一种组合物,其以将芒果叶和华千金藤相配伍,及其提取物等活性成分,还与其它物质相组合用于糖尿病的预防和治疗。
本发明所称的“芒果苷”,又称知母宁,化学名称为2-β-D-吡喃葡萄糖基-1,3,6,7-四羟基酮,是一种黄酮类化合物。其略溶于甲醇、乙醇、水、可溶于热稀甲醇、热稀乙醇,不溶于非极性溶剂。可以通过化学方法直接合成制得,一般从含有芒果苷的植物或中药材(如:知母)中提取。这类药材经溶媒,如:水、乙醇、甲醇、丙醇、丁醇或纯的水溶液,高温提取、浓缩后在分离等步骤得到纯度大于60%的芒果苷(中国发明专利申请200710066354.6)。这类药材依次经醇提、脱色、去溶剂、稀醇溶解和去溶剂等步骤得到的提取物中芒果苷纯度大于90%(中国发明专利申请200610079234.5)。这些含有芒果苷的药材如:但不仅限于,芒果叶、扁桃叶、知母和石韦等。
本发明所称的“罗通定”系CAS No.:10097-84-4的化合物,白色或微黄色的结晶;无臭,无味;遇光受热易变黄。在氯仿中溶解,在乙醇或乙醚中略溶,在水中不溶;在稀硫酸中易溶。熔点为141℃~144℃。
本发明所称的组合物,还包括各种与所含化合物或组合物相适应的药物辅料,以制成有利于给药(drug delivery)的剂型,如:但不仅限于水溶液注射剂、粉针剂、丸剂、散剂、片剂、贴剂、栓剂、乳剂、霜剂、凝胶剂、颗粒剂、胶囊剂、气雾剂、喷雾剂、粉雾剂、缓释剂和控释剂等。这些药用辅料既可以是各种制剂中常规使用的,如:但不仅限于等渗剂、缓冲液、矫味剂、赋形剂、填充剂、粘合剂、崩解剂和润滑剂等;也可以是为了与所述物质相适应而选择使用的,如:乳化剂、增溶剂、抑菌剂、止痛剂和抗氧剂等,这类辅料能有效提高组合物所含化合物的稳定性和溶解性或改变化合物的释放速率和吸收速率等,从而改善各种化合物在生物体内的代谢,进而增强组合物的给药效果。此外,还可以为实现特定的给药目的或方式,如:缓释给药、控释给药和脉冲给药等,而使用的辅料,如:但不仅限于明胶、白蛋白、壳聚糖、聚醚和聚酯类高分子材料,如:但不仅限于,聚乙二醇、聚氨酯、聚碳酸酯及其共聚物等。所称的“有利于给药”的主要表现有:但不仅限于提高治疗效果、提高生物利用度、降低毒副作用和提高患者顺应性等。
在水溶液注射剂中,辅料一般包括等渗剂和缓冲液,以及必要的乳化剂(如:Tweeen-80、Pluronic和Poloxamer等)、增溶剂和抑菌剂等。此外,还包括含有药学上可接受的其它药用辅料,如:抗氧剂、pH调节剂和止痛剂等。
用于制取口服液体制剂的辅料一般包括溶剂,以及必要的矫味剂、抑菌剂、乳化剂和着色剂等。
用于制取片剂的辅料一般包括填充剂(如:淀粉、糖粉、糊精、乳糖、可压性淀粉、微晶纤维素、硫酸钙、磷酸氢钙和甘露醇等)、粘合剂(如:乙醇、淀粉浆、羧甲基纤维素钠、羟丙基纤维素、甲基纤维素、乙基纤维素、羟丙基甲基纤维素、明胶溶液、蔗糖溶液和聚乙烯吡咯烷酮的水溶液或醇溶液等)、崩解剂(如:干淀粉、羧甲基淀粉钠、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮和交联羧甲基纤维素钠)和润滑剂(如:硬脂酸镁、微粉硅胶、滑石粉、氢化植物油、聚乙二醇4,000、聚乙二醇6,000和月桂醇硫酸镁等)等。
用于制取乳剂的辅料一般为水、油(如:脂肪酸)、乳化剂,以及必要的防腐剂和矫味剂等。
用于制取颗粒剂的辅料与片剂类似,但造粒过程不同。根据需要,将制得的颗粒剂与助流剂混合后装入胶囊即得胶囊剂。
本发明所称的“生物体”、“动物”或“患者”是指人、野生动物和家畜(Livestock)。野生动物为自然状态下未经人工驯化的动物。家畜是为了提供食物来源而人工饲养的动物,如:但不仅限于狗、猫、鼠、大鼠、仓鼠、猪、兔、奶牛、水牛、公牛、绵羊、山羊、鹅和鸡等。给予治疗的“患者”或“生物体”优先选择哺乳动物,尤其是人。
本发明所称的“预防”是指在未被临床标准认定的疾病前,各种用于防止疾病发生或发展的手段或措施,包括医学、物理或化学的方法,以阻止和降低疾病各种症状的发生或发展。
本发明所称的“预防糖尿病”是指将本发明组合物用于还未符合“糖尿病”临床指标的,随着时间的延续将慢慢发展成为临床上定义为“糖尿病”的潜在患者,从而改善这些患者对葡萄糖的耐受,促进肌体对糖代谢的能力,增加肌体对胰岛素的敏感性。这类潜在的患者通常患有“代谢综合症(Metabolic Syndrome)”(Annnu.Rev.Nutri.,2005,25,391-406;Annnu.Rev.Med.,2005,56,45-62;Nat.Rev.Drug.Disc.,2006,5,295-309;Nat.Rev.Endocri.,2006,2,335-348),如:肥胖、胰岛素抵制、葡萄糖不耐受、高血压、动脉硬化证(antherosclerosis)、血脂异常症(dyslipidemia)(即血液中的甘油三酯水平偏高,高密度脂蛋白同时偏低)等。
本发明所称的“治疗”是指为了阻止和降低疾病的发生或发展,使疾病病程的发展或加重得以抑制、遏制、减轻、改善、减缓、停止、延迟或反转,所描述的保持和/或用药时的疾病的、紊乱的或病理学状态的各种指标包括减轻或减少症状或并发症,或治愈或消除疾病、紊乱或状况。
本发明所称的“治疗糖尿病”是指将本发明组合物用于临床诊断为“糖尿病”的患者,改善这些患者对葡萄糖的耐受,促进肌体对糖代谢的能力,增加肌体对胰岛素的敏感性。进而使得患者的餐后和空腹血糖得以控制在正常的水平。由于对葡萄糖代谢的能力得以提高,从而减缓了因长期高血糖而产生的各种心血管疾病、慢性肾衰竭、视网膜病变、神经病变及微血管病变的发生和发展。
本发明所称的“食品”是指包括本发明提供的各种化合物、组合物或提取物制成可食用的单一化合物或组合物。该种单一化合物或组合物的生产和制造应当符合相关食品安全标准,但是这些食品安全标准不得限定本发明。
本发明所称的“保健品”是指将包括本发明提供的各种化合物、组合物或提取物制成可食用的单一化合物或组合物以施于患者,起到对疾病进行预防和治疗的目的。其属于本发明所称的食品,但其生产、制造和销售还应当符合各种相关的要求、标准和规范。
本发明所称的“药物”是指可以用于预防或治疗某种疾病的单一化合物、多种化合物形成的组合物、中药材及其提取物,或指以单一化合物为主要活性成分的组合物或制剂(formulation),还指由多种化合物为活性成分的组合物或制剂。“药物”应理解为不仅指根据一国之法律规定,通过其设立的行政机构审批并准予生产的产品,还指在为了获得通过审批和准予生产的过程中,所形成的含单一化合物为活性成分的各类物质形态。“形成”应理解为通过化学合成、生物转化或购买等途径获得。
本发明提供的一种组合物,将芒果叶和华千金藤相配伍,按重量两种成分的配伍关系为:芒果叶0.3份~7份,华千金藤0.1~5份。由此使得组合物能起到改善血糖和糖化血红蛋白的药理作用。
本发明提供的另一种组合物,将芒果叶和华千金藤相配伍,按重量两种成分的配伍关系为:芒果叶1~3份,华千金藤0.2~2份。由此使得组合物能起到改善血糖和糖化血红蛋白的药理作用。
本发明提供的另一种组合物,将芒果叶和华千金藤相配伍,按重量两种成分的配伍关系为:芒果叶1~3份,华千金藤0.5~1份。由此使得组合物能起到改善血糖和糖化血红蛋白的药理作用。
本发明还发现,芒果叶和华千金藤提取物亦有改善血糖和糖化血红蛋白的药理作用。
本发明提供的另一种组合物,按重量份取芒果叶0.3份~7份,华千金藤0.1~5份,加50v/v%~90v/v%乙醇回流提取2次,其中,第1次为8倍量50v/v%~90v/v%乙醇,1~3小时,第2次为6倍量50v/v%~90v/v%乙醇,1~2小时,滤过后,合并2次滤液,减压回收乙醇至无醇味,继续减压浓缩至50℃±5℃时相对密度为1.20~1.34,得提取物。
本发明提供的另一种组合物,按重量份取芒果叶1~3份,华千金藤0.2~2份,加50v/v%~80v/v%乙醇回流提取2次,其中,第1次为8倍量50v/v%~90v/v%乙醇,1~3小时,第2次为6倍量50v/v%~90v/v%乙醇,1~2小时,滤过后,合并2次滤液,减压回收乙醇至无醇味,继续减压浓缩至50℃±5℃时相对密度为1.20~1.34,得提取物。
本发明提供的另一种组合物,按重量份取芒果叶1~3份,华千金藤0.5~1份,加50v/v%~90v/v%乙醇回流提取2次,其中,第1次为8倍量50v/v%~90v/v%乙醇,1~3小时,第2次为6倍量50v/v%~90v/v%乙醇,1~2小时,滤过后,合并2次滤液,减压回收乙醇至无醇味,继续减压浓缩至50℃±5℃时相对密度为1.20~1.34,得提取物。
进一步研究发现,芒果苷和罗通定为活性成分,亦表现出改善血糖和糖化血红蛋白的药理作用。
本发明提供的另一种组合物,其以芒果苷和罗通定为活性成分,按重量两种成分的配伍关系为:芒果苷10%~90%,罗通定10%~90%。
本发明提供的另一种组合物,其以芒果苷和罗通定为活性成分,按重量两种成分的配伍关系为:芒果苷51%~90%,罗通定10%~49%。
本发明提供的另一种组合物,其以芒果苷和罗通定为活性成分,按重量两种成分的配伍关系为:芒果苷61%~90%,罗通定10%~39%。
本发明提供的各种组合物,具有改善血糖的药理作用,可以作为唯一的或主要的活性成分而应用于制取各种预防和治疗糖尿病的药物、食品和保健品,或与其它一种或多种具有改善糖尿病的化学物质或药物一并给予生物体。这些化学物质如:但不仅限于芒果叶提取物、华千金藤提取物、芒果苷和罗通定等。所称的“一并给予生物体”是指本发明各种化合物单独或与其它一种或多种具有改善糖尿病的化合物、提取物或药物混合后经单一的给药途径,如:但不仅限于,口服(Oral)、鼻腔(Nasal)、(面)颊(Buccal)、透皮(Transdermal)、肺部(Pulmonal)、阴道(Vaginal)、皮下(Subcutaneous)或静脉(Intravenous)给予生物体;或与其它一种或多种具有改善糖尿病的化学物质或药物分别经多种的给药途径给予生物体。
本发明提供的一种药物组合物,以本发明提供的组合物为活性成分。
本发明提供的另一种食品,以本发明提供的组合物为活性成分。
本发明提供的另一种保健品,以本发明提供的组合物为活性成分。
本发明技术方案实现的有益效果:
本发明提供的组合物,将芒果叶和华千金藤相配伍,使得两者配伍后具有改善血糖和糖化血红蛋白的药理作用,具有药物的开发前景。
本发明提供的组合物,将芒果叶和华千金藤提取物相配伍,使得两者配伍后具有改善血糖和糖化血红蛋白的药理作用,具有食品、保健品和药物的开发前景。
本发明提供的组合物,以芒果苷和罗通定为活性成分,亦表现出改善血糖和糖化血红蛋白的药理作用。
具体实施方式
以下详细描述本发明的技术方案。本发明实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的精神和范围,其均应涵盖在本发明的权利要求范围中。
本发明所用的试剂若未明确指明,则均购自于西格玛-奥德里奇(Sigma-Aldrich)。
实施例1芒果叶和华千金藤相配伍
芒果叶0.3份~7份和华千金藤0.1~5份混合,通过制粉或水煎的方式获得供试品1。
实施例2芒果叶和华千金藤提取物的制取
按重量份取芒果叶0.3份~7份,华千金藤0.1~5份,加90%乙醇回流提取2次,第1次乙醇为8倍量,2小时,第2次乙醇为6倍量,1小时,双层纱布滤过,合并2次滤液,减压回收乙醇至无醇味,继续减压浓缩至55℃时相对密度为1.30,得提取物,记为供试品2。
实施例3芒果苷的制取
参考《中成药》2012年第34卷第1期第161页的内容,制取芒果苷单体化合物,并进行结构鉴定,数据如下:
ESIMS(m/z)421[M-H]-。
1H-NMR(400MHz,Pyridine-d5)δ14.62(s,1H),8.11(s,1H),7.18(s,1H),6.64(s,1H),5.88(d,J=10.0Hz,1H),5.28-5.23(m,1H),4.60(d,J=10.4Hz,1H),4.53-4.44(m,3H),4.25-4.23(m,1H)。
13C-NMR(100MHz,Pyridine-d5)δ182.4,167.3,165.2,159.6,158.1,154.1,147.5,115.2,111.3,110.9,105.4,104.8,96.3,85.0,82.7,77.6,74.8,74.0,64.9。
也可以获得该化合物商品,如:武汉宏信康精细化工公司。
实施例4罗通定的制取
参考《广西化工》1996年第25卷第2期第4页的内容,制取罗通定单体化合物,并进行结构鉴定,数据如下:
HR-MS,m/z:356.1856[M+H]+。
1H-NMR(600MHz,CD3OD),δ:6.91(d,1H,J=8.4Hz),6.87(d,1H,J=8.4Hz),6.84(s,1H),6.69(s,1H),4.17(d,1H,J=15.6Hz),3.81(s,9H),3.78(s,3H),3.48(d,1H,J=11.4Hz),3.46(d,1H,J=15.6Hz),3.40(dd,1H,J=16.2,3.6Hz),3.17(dd,1H,J=11.4,3.6Hz),3.07(td,1H,J=16.2),2.66~3.04(m,2H),2.59(td,1H,J=11.4,3.6Hz)。
13C-NMR(150MHz,CD3OD)δ:151.7,149.2,149.1,146.2,130.6,128.9,128.6,127.8,125.2,112.9,112.6,110.4,60.8,60.5,56.7,56.4,56.3,54.8,52.7,36.5,29.3。
也可以获得该化合物商品,如:武汉兴众诚科技有限公司。
实施例5以芒果苷和罗通定为活性成分配伍
按重量,将制得的或购得的芒果苷和罗通定用量:芒果苷10%~90%,罗通定10%~90%配伍,制得2组组合物,记为供试品3和供试品4。
实施例6对自发性糖尿病GK大鼠血糖的影响
取血糖稳定值>9.0mmol/L的35只GK雄性大鼠,随机分成5组,每组7只,分别为模型对照组、供试品1~供试品4的本发明药物组合物组,另以7只同周龄Wistar大鼠为正常对照组。灌胃给药。
采用强生稳豪型血糖仪,剪尾取血测定血糖。随机血糖上午9~10时测定;空腹血糖为禁食6小时血糖(上午9时禁食下午3时测定)。
试验结束前剪尾取血,采用Bio-Rad公司HbA1c测定仪测定糖化血红蛋白(HbA1c)。
结果参见表1、表2和表3。
表1本发明组合物对GK大鼠空腹血糖的影响
表1中,*p<0.05,**p<0.01与模型对照组比较。
表1可见,本发明各个组合物各供试品均具有降低GK大鼠空腹血糖(p<0.05,p<0.01),且效果显著,单体化合物组合的药效优于药材组合。
表2本发明组合物对GK大鼠随机血糖的影响
表2中,*p<0.05,**p<0.01与模型对照组比较。
表2可见,本发明各个组合物各供试品均能显著降低GK大鼠随机血糖(p<0.05,p<0.01),且效果显著,单体化合物组合的药效优于药材组合。
表3本发明组合物对GK大鼠糖化血红蛋白(HbA1c)的影响
表3中,*p<0.05,**p<0.01与模型对照组比较。
表3可见,与模型组相比,本发明各个组合物给药4周后糖化血红蛋白(HbA1c)下降显著(p<0.05,p<0.01),提示本发明各个组合物可以有效降低GK大鼠的长期高血糖状态。
Claims (9)
1.一种组合物,其特征在于按重量份取芒果叶0.3份~7份,华千金藤0.1~5份,加50v/v%~90v/v%乙醇回流提取2次,其中,第1次为8倍量50v/v%~90v/v%乙醇,1~3小时,第2次为6倍量50v/v%~90v/v%乙醇,1~2小时,滤过后,合并2次滤液,减压回收乙醇至无醇味,继续减压浓缩至50℃±5℃时相对密度为1.20~1.34,得提取物。
2.一种组合物,其特征在于按重量份取芒果叶1~3份,华千金藤0.2~2份,加50v/v%~80v/v%乙醇回流提取2次,其中,第1次为8倍量50v/v%~90v/v%乙醇,1~3小时,第2次为6倍量50v/v%~90v/v%乙醇,1~2小时,滤过后,合并2次滤液,减压回收乙醇至无醇味,继续减压浓缩至50℃±5℃时相对密度为1.20~1.34,得提取物。
3.一种组合物,其特征在于按重量份取芒果叶1~3份,华千金藤0.5~1份,加50v/v%~90v/v%乙醇回流提取2次,其中,第1次为8倍量50v/v%~90v/v%乙醇,1~3小时,第2次为6倍量50v/v%~90v/v%乙醇,1~2小时,滤过后,合并2次滤液,减压回收乙醇至无醇味,继续减压浓缩至50℃±5℃时相对密度为1.20~1.34,得提取物。
4.根据权利要求1~3所述的组合物在制备预防和治疗糖尿病的药物、食品或保健品中的应用。
5.根据权利要求1~3所述的组合物在制备改善糖化血红蛋白的药物、食品或保健品中的应用。
6.一种用于预防和治疗糖尿病的组合物,以权利要求1~3之一所述的组合物为活性成分。
7.根据权利要求6所述的用于预防和治疗糖尿病的组合物,其特征在于所述的组合物为药物。
8.根据权利要求6所述的用于预防和治疗糖尿病的组合物,其特征在于所述的组合物为食品。
9.根据权利要求6所述的用于预防和治疗糖尿病的组合物,其特征在于所述的组合物为保健品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611173840.3A CN106491718A (zh) | 2016-12-16 | 2016-12-16 | 制取自两种植物药的组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611173840.3A CN106491718A (zh) | 2016-12-16 | 2016-12-16 | 制取自两种植物药的组合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106491718A true CN106491718A (zh) | 2017-03-15 |
Family
ID=58333182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611173840.3A Pending CN106491718A (zh) | 2016-12-16 | 2016-12-16 | 制取自两种植物药的组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106491718A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008061480A1 (en) * | 2006-11-24 | 2008-05-29 | Hainan Deze Drug Research Co., Ltd | Novel mangiferin calcium salts, the method for its preparation and its use |
CN101327214A (zh) * | 2008-07-18 | 2008-12-24 | 中国药科大学 | 异喹啉生物碱类作为组织因子抑制剂的医药用途 |
CN103169743A (zh) * | 2013-04-24 | 2013-06-26 | 天津中医药大学 | 芒果叶提取物、其制备方法及用途 |
CN103768112A (zh) * | 2012-10-26 | 2014-05-07 | 昆明制药集团股份有限公司 | 一种芒果叶提取物及其应用 |
-
2016
- 2016-12-16 CN CN201611173840.3A patent/CN106491718A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008061480A1 (en) * | 2006-11-24 | 2008-05-29 | Hainan Deze Drug Research Co., Ltd | Novel mangiferin calcium salts, the method for its preparation and its use |
CN101327214A (zh) * | 2008-07-18 | 2008-12-24 | 中国药科大学 | 异喹啉生物碱类作为组织因子抑制剂的医药用途 |
CN103768112A (zh) * | 2012-10-26 | 2014-05-07 | 昆明制药集团股份有限公司 | 一种芒果叶提取物及其应用 |
CN103169743A (zh) * | 2013-04-24 | 2013-06-26 | 天津中医药大学 | 芒果叶提取物、其制备方法及用途 |
Non-Patent Citations (1)
Title |
---|
曹春林 等: "《中药制剂注解》", 28 February 1993, 上海科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN106176918A (zh) | 一种包含青钱柳叶和葛根的降血糖保健组合物 | |
CN103933346B (zh) | 一种降糖组合物及其制备方法 | |
CN106177183A (zh) | 一种包含青钱柳叶、绿茶和桑叶的降血糖保健组合物 | |
CN102631526B (zh) | 一种用于治疗糖尿病的中药组合物 | |
CN104857154A (zh) | 一种治疗“三高”症的中药组合物及其制备方法 | |
CN105125946A (zh) | 一种清心除烦的栀子口服液及其制备方法 | |
CN103055176B (zh) | 一种治疗糖尿病的中药及其制备方法 | |
CN102579530A (zh) | 具有抗糖尿病作用的太白楤木总皂苷的制备方法及药物 | |
CN103432420B (zh) | 一种治疗糖尿病的中药组合物及其制备方法和检测方法 | |
CN100423754C (zh) | 治疗慢性酒精中毒性肝病的药物及其制备方法 | |
CN105267944A (zh) | 一种用于糖尿病及其并发症的水蛭小肽有效部位药物 | |
CN101455778B (zh) | 一种清热利咽的中药制剂及其制备方法 | |
CN102018852A (zh) | 参连消渴降糖胶囊及制作工艺 | |
CN101219200B (zh) | 一种中药软胶囊及其制备方法 | |
CN101204509B (zh) | 一种中药软胶囊及其制备方法 | |
CN106491718A (zh) | 制取自两种植物药的组合物及其用途 | |
CN102552378A (zh) | 紫花苜蓿及其提取物在制备治疗糖尿病药物中的应用 | |
CN106581161A (zh) | 治疗和预防糖代谢异常的组合物及其用途 | |
CN105641672A (zh) | 治疗能量代谢失衡引起的肥胖症的组合物及制剂 | |
CN110384709A (zh) | 含有根皮苷和1-脱氧野尻霉素的组合物及其应用 | |
CN101249129B (zh) | 一种治疗糖尿病的中药提取物组合物及其医药用途 | |
CN101406576B (zh) | 一种治疗糖尿病的中药及制备方法 | |
CN106580977A (zh) | 黄酮与生物碱的组合物及其用途 | |
CN106474194A (zh) | 两种植物药的组合及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170315 |